Result of AGM

29 April 2020 16:00 BST

Results of Annual General Meeting held on 29 April 2020

AstraZeneca PLC announced the results of the voting at its Annual General Meeting (AGM) today. As proposed in the Notice of AGM, all Resolutions were decided by poll vote. Resolutions 10 - 13 were passed as special resolutions; all other resolutions were passed as ordinary resolutions.

RESOLUTION VOTES FOR % OF VOTES CAST VOTES AGAINST % OF VOTES CAST VOTES CAST IN TOTAL TOTAL VOTES CAST AS A % OF ISSUED SHARE CAPITAL VOTES WITHHELD
1 To receive the Company's Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended 31 December 2019  1,061,180,101 99.92 872,215 0.08 1,062,052,316 80.93% 7,121,452
2 To confirm dividends  1,058,995,786 99.10 9,598,531 0.90 1,068,594,317 81.43% 579,469
3 To reappoint PricewaterhouseCoopers LLP as Auditor  1,068,300,235 99.97 312,449 0.03 1,068,612,684 81.43% 560,776
4 To authorise the Directors to agree the remuneration of the Auditor  1,067,398,628 99.90 1,086,858 0.10 1,068,485,486 81.42% 687,961
5a To re-elect Leif Johansson as a Director  1,065,113,167 99.69 3,276,071 0.31 1,068,389,238 81.42% 784,805
5b To re-elect Pascal Soriot as a Director  1,067,248,723 99.90 1,033,124 0.10 1,068,281,847 81.41% 892,364
5c To re-elect Marc Dunoyer as a Director  1,060,164,242 99.25 8,056,265 0.75 1,068,220,507 81.40% 952,979
5d To re-elect Geneviève Berger as a Director  882,846,920 83.06 179,994,848 16.94 1,062,841,768 80.99% 6,331,650
5e To re-elect Philip Broadley as a Director  1,066,048,992 99.79 2,190,705 0.21 1,068,239,697 81.41% 933,713
5f To re-elect Graham Chipchase as a Director  1,062,682,507 99.48 5,520,936 0.52 1,068,203,443 81.40% 969,967
5g To elect Michel Demaré as a Director  1,066,252,259 99.82 1,969,593 0.18 1,068,221,852 81.40% 951,558
5h To re-elect Deborah DiSanzo as a Director  1,067,836,362 99.97 351,091 0.03 1,068,187,453 81.40% 985,957
5i To re-elect Sheri McCoy as a Director  1,064,329,862 99.64 3,890,368 0.36 1,068,220,230 81.40% 951,792
5j To re-elect Tony Mok as a Director 1,067,117,370 99.90 1,066,669 0.10 1,068,184,039 81.40% 989,371
5k To re-elect Nazneen Rahman as a Director  1,067,376,963 99.92 821,467 0.08 1,068,198,430 81.40% 973,592
5l To re-elect Marcus Wallenberg as a Director  955,082,665 89.42 113,060,725 10.58 1,068,143,390 81.40% 1,030,019
6 To approve the Annual Report on Remuneration for the year ended 31 December 2019  1,032,308,145 96.65 35,747,783 3.35 1,068,055,928 81.39% 1,118,038
7 To approve the Directors' Remuneration Policy  972,774,742 94.71 54,292,376 5.29 1,027,067,118 78.27% 42,106,679
8 To authorise limited political donations  1,038,907,152 97.75 23,872,400 2.25 1,062,779,552 80.99% 6,394,668
9 To authorise the Directors to allot shares  910,654,650 85.26 157,472,093 14.74 1,068,126,743 81.40% 1,046,979
10 To authorise the Directors to disapply pre-emption rights  1,058,066,972 99.23 8,200,338 0.77 1,066,267,310 81.26% 2,906,339
11 To authorise the Directors to further disapply pre-emption rights for acquisitions and specified capital investments  1,054,711,677 98.92 11,513,414 1.08 1,066,225,091 81.25% 2,948,557
12 To authorise the Company to purchase its own shares  1,051,131,060 98.41 16,950,800 1.59 1,068,081,860 81.39% 1,091,896
13 To reduce the notice period for general meetings  998,062,805 93.44 70,101,553 6.56 1,068,164,358 81.40% 1,008,865
14 To approve the 2020 Performance Share Plan 1,010,149,491 95.66 45,877,396 4.34 1,056,026,887 80.48% 13,147,356

 

Issued capital

As at 27 April 2020, the number of issued shares of the Company was 1,312,240,429 ordinary shares, which was the total number of shares entitling the holders to attend and vote for or against all of the resolutions at the AGM. In accordance with the Company's Articles of Association, on a poll every member present in person or by proxy has one vote for every share held.

AstraZeneca

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal and Metabolism, and Respiratory. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

 

Adrian Kemp
Company Secretary
AstraZeneca PLC


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

About Us

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of US $32.8 billion in 2009. For more information please visit: www.astrazeneca.com

Subscribe

Documents & Links